ERR2598250
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 9
- umap1_2d
- -4.474276291
- umap2_2d
- 2.780011326
- umap1_3d
- -2.726238999
- umap2_3d
- 2.781586222
- umap3_3d
- -1.422717694
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.580
- MYC_TARGETS_V1+0.560
- DNA_REPAIR+0.490
- G2M_CHECKPOINT+0.480
- MYC_TARGETS_V2+0.420
- WNT_BETA_CATENIN_SIGNALING+0.370
- PANCREAS_BETA_CELLS+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.270
- OXIDATIVE_PHOSPHORYLATION+0.240
- SPERMATOGENESIS+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INFLAMMATORY_RESPONSE-0.520
- IL6_JAK_STAT3_SIGNALING-0.500
- INTERFERON_GAMMA_RESPONSE-0.490
- ALLOGRAFT_REJECTION-0.460
- UV_RESPONSE_DN-0.460
- TNFA_SIGNALING_VIA_NFKB-0.450
- COMPLEMENT-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- KRAS_SIGNALING_UP-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598256 | fetal | fetal | 0.984 |
| 2 | ERR2598235 | fetal | fetal | 0.966 |
| 3 | ERR2598212 | fetal | fetal | 0.960 |
| 4 | ERR2598206 | fetal | fetal | 0.929 |
| 5 | BS_8SKZ7BRN | low-grade glioma | — | 0.928 |
| 6 | C3L-01285 | — | cohortSQ2 | 0.924 |
| 7 | BS_37GTVG4N | Embryonal tumors | — | 0.923 |
| 8 | BS_K25F4J3V | ATRT | — | 0.916 |
| 9 | BS_JZRM1S3T | medulloblastoma | — | 0.916 |
| 10 | 20120209.TNBC | — | E | 0.914 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.490 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |